New RSV vaccine LYB005 enters human trials for seniors

NCT ID NCT07208461

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new vaccine called LYB005 against RSV, a virus that can cause serious lung infections in older adults. About 700 volunteers aged 60 and older will receive either the vaccine or a placebo. Researchers will check how well the vaccine boosts the immune system and whether it is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LYB005 RSV vaccine (with or without A01B adjuvant)

What this could lead to

If successful, this could lead to a safe and effective RSV vaccine for older adults, reducing severe respiratory infections.

What could go wrong

This is an early Phase 2 trial, so results may not confirm effectiveness. The vaccine might not produce strong enough immunity or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Disease Control and Prevention of Dangyang City

    Dangyang, China